VRME
VerifyMe, Inc.
Security & Protection Services
Market Cap$9M
5Y Perf.-44.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VRME vs INTS
Revenue, margins, valuation, and 5-year total return — side by side.
INTS
Intensity Therapeutics, Inc.
Biotechnology
Market Cap$13M
5Y Perf.-96.6%
VRME vs INTS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VRME | INTS |
|---|---|---|
| Industry | Security & Protection Services | Biotechnology |
| Market Cap | $9M | $13M |
| Revenue (TTM) | $22M | $0.00 |
| Net Income (TTM) | $-5M | $-12M |
| Gross Margin | 34.9% | — |
| Operating Margin | -7.7% | — |
| Total Debt | $2M | $138K |
| Cash & Equiv. | $3M | $3M |
VRME vs INTS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VRME
INTS
| Stock | Jun 23 | May 26 | Return |
|---|---|---|---|
| VerifyMe, Inc. (VRME) | 100 | 56.0 | -44.0% |
| Intensity Therapeut… (INTS) | 100 | 3.4 | -96.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VRME vs INTS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VRME leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Intensity Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
VRME
VerifyMe, Inc.
The Long-Run Compounder
VRME carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -94.8% 10Y total return vs INTS's -96.6%
- -4.4% revenue growth vs INTS's -74.2%
- +10.7% vs INTS's -62.9%
Best for: long-term compounding
INTS
Intensity Therapeutics, Inc.
The Income Pick
INTS is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.87
- EPS growth 15.2%
- Lower volatility, beta 1.87, Low D/E 4.7%, current ratio 1.92x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VRME | -4.4% revenue growth vs INTS's -74.2% |
| Quality / Margins | INTS | 6.6% margin vs VRME's -21.8% |
| Stability / Safety | INTS | Beta 1.87 vs VRME's 2.16, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | VRME | +10.7% vs INTS's -62.9% |
| Efficiency (ROA) | VRME | -29.7% ROA vs INTS's -214.6%, ROIC -14.1% vs -475.7% |
VRME vs INTS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
VRME vs INTS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLVRMELAGGINGINTS
INTSIntensity Therapeutic…
1leads
VRMEVerifyMe, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs INTSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INTS1/1
Valuation MetricsMultiples, price ratios, and targets
VRME2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
VRME5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
VRME6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
INTS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
VRME and INTS operate at a comparable scale, with $22M and $0 in trailing revenue.
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| RevenueTrailing 12 months | $22M | $0 |
| EBITDAEarnings before interest/tax | -$514,000 | -$9M |
| Net IncomeAfter-tax profit | -$5M | -$12M |
| Free Cash FlowCash after capex | $615,000 | -$10M |
| Gross MarginGross profit ÷ Revenue | +34.9% | — |
| Operating MarginEBIT ÷ Revenue | -7.7% | — |
| Net MarginNet income ÷ Revenue | -21.8% | — |
| FCF MarginFCF ÷ Revenue | +2.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -13.0% | +75.2% |
INTS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
VRME leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| Market CapShares × price | $9M | $13M |
| Enterprise ValueMkt cap + debt − cash | $9M | $11M |
| Trailing P/EPrice ÷ TTM EPS | -2.09x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.39x | — |
| Price / BookPrice ÷ Book value/share | 0.79x | 0.97x |
| Price / FCFMarket cap ÷ FCF | 27.20x | — |
VRME leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
VRME leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
VRME delivers a -37.5% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-4 for INTS. INTS carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRME's 0.22x. On the Piotroski fundamental quality scale (0–9), VRME scores 6/9 vs INTS's 1/9, reflecting solid financial health.
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -37.5% | -3.7% |
| ROA (TTM)Return on assets | -29.7% | -2.1% |
| ROICReturn on invested capital | -14.1% | -4.8% |
| ROCEReturn on capital employed | -15.2% | -2.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 |
| Debt / EquityFinancial leverage | 0.22x | 0.05x |
| Net DebtTotal debt minus cash | -$601,000 | -$2M |
| Cash & Equiv.Liquid assets | $3M | $3M |
| Total DebtShort + long-term debt | $2M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -52.63x | — |
VRME leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
VRME leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VRME five years ago would be worth $1,889 today (with dividends reinvested), compared to $343 for INTS. Over the past 12 months, VRME leads with a +10.7% total return vs INTS's -62.9%. The 3-year compound annual growth rate (CAGR) favors VRME at -25.4% vs INTS's -67.5% — a key indicator of consistent wealth creation.
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| YTD ReturnYear-to-date | +14.5% | -49.8% |
| 1-Year ReturnPast 12 months | +10.7% | -62.9% |
| 3-Year ReturnCumulative with dividends | -58.5% | -96.6% |
| 5-Year ReturnCumulative with dividends | -81.1% | -96.6% |
| 10-Year ReturnCumulative with dividends | -94.8% | -96.6% |
| CAGR (3Y)Annualised 3-year return | -25.4% | -67.5% |
VRME leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VRME and INTS each lead in 1 of 2 comparable metrics.
Risk & Volatility
INTS is the less volatile stock with a 1.87 beta — it tends to amplify market swings less than VRME's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRME currently trades 51.2% from its 52-week high vs INTS's 11.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.16x | 1.87x |
| 52-Week HighHighest price in past year | $1.51 | $43.50 |
| 52-Week LowLowest price in past year | $0.59 | $0.40 |
| % of 52W HighCurrent price vs 52-week peak | +51.2% | +11.7% |
| RSI (14)Momentum oscillator 0–100 | 42.5 | 36.9 |
| Avg Volume (50D)Average daily shares traded | 102K | 32K |
Evenly matched — VRME and INTS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VRMEVerifyMe, Inc. | INTSIntensity Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.00 |
| # AnalystsCovering analysts | — | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
VRME leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). INTS leads in 1 (Income & Cash Flow). 1 tied.
Best OverallVerifyMe, Inc. (VRME)Leads 3 of 6 categories
Loading custom metrics...
VRME vs INTS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VRME or INTS a better buy right now?
Analysts rate Intensity Therapeutics, Inc.
(INTS) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VRME or INTS?
Over the past 5 years, VerifyMe, Inc.
(VRME) delivered a total return of -81. 1%, compared to -96. 6% for Intensity Therapeutics, Inc. (INTS). Over 10 years, the gap is even starker: VRME returned -94. 8% versus INTS's -96. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VRME or INTS?
By beta (market sensitivity over 5 years), Intensity Therapeutics, Inc.
(INTS) is the lower-risk stock at 1. 87β versus VerifyMe, Inc. 's 2. 16β — meaning VRME is approximately 16% more volatile than INTS relative to the S&P 500. On balance sheet safety, Intensity Therapeutics, Inc. (INTS) carries a lower debt/equity ratio of 5% versus 22% for VerifyMe, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VRME or INTS?
On earnings-per-share growth, the picture is similar: Intensity Therapeutics, Inc.
grew EPS 15. 2% year-over-year, compared to -5. 7% for VerifyMe, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VRME or INTS?
Intensity Therapeutics, Inc.
(INTS) is the more profitable company, earning 0. 0% net margin versus -15. 8% for VerifyMe, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INTS leads at 0. 0% versus -8. 6% for VRME. At the gross margin level — before operating expenses — VRME leads at 35. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VRME or INTS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VRME or INTS better for a retirement portfolio?
For long-horizon retirement investors, Intensity Therapeutics, Inc.
(INTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. VerifyMe, Inc. (VRME) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INTS: -96. 6%, VRME: -94. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VRME and INTS?
These companies operate in different sectors (VRME (Industrials) and INTS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.